Pharma Equity Group (One-pager): Repositioning Strategy at an Inflection Point
Summary
- Pharma Equity Group (PEG) maintains its guidance for DKK 11m in partner-driven revenue, supported by the approval to initiate its RNX-011 Phase IIb clinical trial, enhancing its partner negotiation position.
- We expect PEG's medium-term cash burn to remain moderate, with plans to out-license pipeline assets based on Phase IIb results, despite limited cash-on-hand and a lean cost base of DKK 5–6m per quarter.
- The company's near-term capital position relies on securing a partner agreement or settling the Portinho receivable, with short-term financing or equity capital raise as potential solutions to bridge funding gaps.
- Our valuation assigns a 31% Probability of Success for regulatory approval and commercialization through partnerships, slightly above the 29% benchmark for Phase II products attaining FDA approval.
This content is generated by AI. You can give feedback on it in the Inderes forum.
PEG maintained its guidance with its H1 2025 results, for DKK 11m in partner-driven revenue. The recent approval to initiate its RNX- 011 Phase IIb clinical trial strengthens PEG’s partner negotiation position. Medium-term cash burn should remain moderate with plans to fully out-license pipeline assets based on Phase IIb results. Despite limited cash-on-hand, PEG maintains a lean cost base of around DKK 5–6m per quarter. The near-term capital position is contingent on an imminent partner agreement or settlement of the Portinho receivable with book value DKK 58m. Short-term financing or an equity capital raise may be used to bridge the funding gap as PEG develops towards cash flow break- even, driven by milestones and royalties from partner agreements.
From a valuation perspective, our base case assigns around 31% Probability of Success (PoS) to achieve regulatory approval and commercialize the pipeline through partnerships. This compares to a benchmark POS of 29% for a Phase II product attaining FDA approval, across indications, according to Biostatistics.
HC Andersen Capital receives payment from Pharma Equity Group for a Digital IR subscription agreement. /Claus Thestrup, 10 September 2025, 08:31 AM.